Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe

Group 1: Legal Investigation - Sanofi SA's Paris headquarters was visited by tax investigators amid a financial probe into alleged "money laundering of tax fraud" [1] - The preliminary investigation, launched in January 2024, may involve organized groups and possible criminal conspiracy [1] - Sanofi claims compliance with all applicable laws and intends to cooperate with authorities [2] Group 2: Product Approval - The European Commission approved Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above [3] - Approval is based on data from two Phase 3 clinical trials in the LIBERTY-CUPID program, showing significant reduction in urticaria activity compared to placebo [4] - Dupixent also increased the percentage of patients with well-controlled disease and complete response at 24 weeks compared to placebo [5]